Aerosolised pentamidine for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Aerosolised pentamidine for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

Rev Inst Med Trop Sao Paulo. 1990 Jul-Aug;32(4):289-95. Unique Identifier : AIDSLINE MED/91327114
Weinberg A; Dantonio SA; Duarte MI; Pedreira Junior WL; Barone AA; Ishioka S; Division of Infectious Diseases, Hospital das Clinicas of the; University of Sao Paulo School of Medicine, Brazil.

Abstract: The goal of this study was to evaluate inhaled pentamidine for the treatment of patients with mild and moderate Pneumocystis carinii pneumonitis. Eight adults with AIDS and pneumocystis pneumonia (4 with a first episode and 4 with a repeat pneumocystosis) received daily inhalations of aerosol pentamidine isethionate for 21 days. Six patients were treated with doses of 300 mg of pentamidine and the remaining 2 received 600 mg every day. In the 300 mg treatment group, 2 individuals showed discrete and transient neutropenia. However, both subjects that received 600 mg of aerosol pentamidine daily developed leukopenia. One of them had major toxicity (overall severe intolerance of 12.5%) that required drug discontinuation and did not allow any analysis of the treatment efficacy. Of the 7 evaluable patients, 6 (88%) completed the treatment successfully. One subject of the 300 mg regimen experienced an early recurrence. In conclusion, inhaled pentamidine is an effective treatment for mild and moderate cases of P. carinii pneumonia. It is less toxic than standard anti-pneumocystis therapy and is suitable for outpatient use.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Administration, Inhalation Adult Female Human Male Middle Age Opportunistic Infections/COMPLICATIONS/*DRUG THERAPY Pentamidine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Pneumonia, Pneumocystis carinii/COMPLICATIONS/*DRUG THERAPY Support, Non-U.S. Gov't JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDcomplicationsadministration,inhalationadultfemalehumanmalemiddleageopportunisticinfections/complications/KWDdrugtherapypentamidine/administration&dosage/KWDtherapeuticusepneumonia,pneumocystiscarinii/complications/KWDdrugtherapysupport,non-uKWDsKWDgov'tjournalarticle
911130
M91B0798

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .